The drugmaker’s pill will take on a rival from Novo Nordisk in the booming multibillion-dollar obesity drug market.

In early April 2026, Eli Lilly received U.S. FDA approval for Foundayo (orforglipron), a once‑daily oral GLP‑1 pill for adults with obesity or overweight and weight‑related medical problems, with U.S.

Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill ...

The daily pill, called Foundayo, could make it easier for more people to lose weight.

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to ...

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form ...

Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as ...

The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe ...

Obesity is known to be a major risk factor that exacerbates metabolic disorders, such as type 2 diabetes. A key molecule ...